Fresenius SE & Co. KGaA

Share Issue/Capital Change • Aug 11, 2008

News Details

Ad-hoc | 11 August 2008 20:15

Fresenius SE: Fresenius resolves on capital increase

Fresenius SE / Capital Increase

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Fresenius resolves on capital increase

The Management Board of Fresenius SE resolved today, with the consent of
the Supervisory Board, to issue up to 2,748,057 new ordinary shares and up
to 2,748,057 new preference shares from authorized capital without
subscription rights.

The new shares will be placed with institutional investors by way of an
accelerated bookbuilt offering. There will be no public offering.

The capital increase is the second component of the long-term financing of
the acquisition of APP Pharmaceuticals, Inc. The residual financing
requirement will consist of debt instruments.

The acquisition of APP Pharmaceuticals is an important step in the growth
strategy of Fresenius Kabi, a business segment of Fresenius SE. With this
acquisition, Fresenius Kabi enters the U.S. pharmaceuticals market and
achieves a leading position in the global I.V. generics market. This North
American platform provides further attractive growth opportunities for
Fresenius Kabi’s existing product portfolio.

The Else Kröner-Fresenius-Foundation has informed us that, as part of the
capital increase, it will purchase approximately 10 % of the new ordinary
shares.

After issuance of the new shares, the total number of outstanding ordinary
shares and preference shares of Fresenius SE will each increase from
currently 77,678,718 to up to 80,426,775.

The new shares are expected to be included in the quotation of the shares
of Fresenius SE in the regulated market at the Frankfurt, Munich and
Düsseldorf stock exchanges. They will have full dividend entitlement for
the fiscal year 2008.

Deutsche Bank and Commerzbank are acting as Joint Lead Managers and Joint
Bookrunners and WestLB as Joint Lead Manager for the offering.

Capital Increase Data

Issuer:Fresenius SE
Transaction Structure:
Capital increase without subscription rights
Offering: Up to 2,748,057 new ordinary shares
Up to 2,748,057 new preference shares
Placement of Shares: Private placement to German and international
institutional investors
Stock Exchanges: Regulated Market Frankfurt (Prime Standard), Munich,
Düsseldorf
Bank Consortium:
Joint Bookrunner: Deutsche Bank AG, Commerzbank AG
Joint Lead Manager: Deutsche Bank AG, Commerzbank AG, WestLB AG

The Management Board

Bad Homburg v.d.H., August, 11 2008

End of note
11.08.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Deutschland
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785638, DE0005785604
WKN: 578563, 578560
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf,
München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg;
Terminbörse EUREX

End of News DGAP News-Service

---